In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

I am delighted that your husband has barreled into fatherhood like an avenging angel. I think that you should sit him down ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Many babies are heading into winter without full protection against the leading cause of severe respiratory illness in ...

The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV ...

People in Northern Ireland are being reminded that a potentially life-saving vaccination aimed at protecting newborns and ...

Experts say new immunisation program working, but some babies missing outThe number of Australian babies admitted to hospital ...